BG63190B1 - Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система - Google Patents

Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система Download PDF

Info

Publication number: BG63190B1
Authority: BG; Bulgaria
Prior art keywords: norcisapride; pharmaceutically acceptable; acceptable salt; composition according; cisapride
Prior art date: 1996-07-19

Application number

BG102757A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG102757A (en

Inventor

John Mccullough

Thomas JERUSSI

Original Assignee

Sepracor Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-19

Filing date

1998-09-09

Publication date

2001-06-29

1998-09-09 Application filed by Sepracor Inc. filed Critical Sepracor Inc.

1999-08-31 Publication of BG102757A publication Critical patent/BG102757A/xx

2001-06-29 Publication of BG63190B1 publication Critical patent/BG63190B1/bg

Links

238000011282 treatment Methods 0.000 title claims abstract description 31
210000003169 central nervous system Anatomy 0.000 title claims abstract description 15
206010047700 Vomiting Diseases 0.000 title claims description 22
239000000203 mixture Substances 0.000 claims abstract description 67
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 46
201000010099 disease Diseases 0.000 claims abstract description 16
230000003474 anti-emetic effect Effects 0.000 claims abstract description 10
ZDLILMQNLSEPLK-UHFFFAOYSA-N 2-chloro-5-methoxy-n-piperidin-4-ylpyrimidin-4-amine Chemical compound COC1=CN=C(Cl)N=C1NC1CCNCC1 ZDLILMQNLSEPLK-UHFFFAOYSA-N 0.000 claims description 65
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 63
239000003814 drug Substances 0.000 claims description 53
239000000126 substance Substances 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 24
208000035475 disorder Diseases 0.000 claims description 19
229940124597 therapeutic agent Drugs 0.000 claims description 19
241000282412 Homo Species 0.000 claims description 18
210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
229940076279 serotonin Drugs 0.000 claims description 15
239000003826 tablet Substances 0.000 claims description 14
206010010774 Constipation Diseases 0.000 claims description 11
230000008673 vomiting Effects 0.000 claims description 10
206010052105 Gastrointestinal hypomotility Diseases 0.000 claims description 9
206010021518 Impaired gastric emptying Diseases 0.000 claims description 9
201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims description 9
201000006549 dyspepsia Diseases 0.000 claims description 9
208000001288 gastroparesis Diseases 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
206010028813 Nausea Diseases 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 8
230000008693 nausea Effects 0.000 claims description 8
238000002560 therapeutic procedure Methods 0.000 claims description 8
206010054048 Postoperative ileus Diseases 0.000 claims description 7
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 6
229940121375 antifungal agent Drugs 0.000 claims description 6
239000003429 antifungal agent Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
230000006870 function Effects 0.000 claims description 6
229960004125 ketoconazole Drugs 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
208000019901 Anxiety disease Diseases 0.000 claims description 5
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 5
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 5
208000019022 Mood disease Diseases 0.000 claims description 5
230000003542 behavioural effect Effects 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
239000007905 soft elastic gelatin capsule Substances 0.000 claims description 5
239000003242 anti bacterial agent Substances 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
239000003443 antiviral agent Substances 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
239000003112 inhibitor Substances 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 3
206010029897 Obsessive thoughts Diseases 0.000 claims description 3
230000000844 anti-bacterial effect Effects 0.000 claims description 3
230000000843 anti-fungal effect Effects 0.000 claims description 3
230000000259 anti-tumor effect Effects 0.000 claims description 3
230000000840 anti-viral effect Effects 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
230000004970 emotional disturbance Effects 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
229960004130 itraconazole Drugs 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims 2
230000036651 mood Effects 0.000 claims 2
238000011321 prophylaxis Methods 0.000 claims 2
206010049119 Emotional distress Diseases 0.000 claims 1
206010013663 drug dependence Diseases 0.000 claims 1
239000006194 liquid suspension Substances 0.000 claims 1
229940001470 psychoactive drug Drugs 0.000 claims 1
239000004089 psychotropic agent Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 21
150000001875 compounds Chemical class 0.000 abstract description 19
239000002111 antiemetic agent Substances 0.000 abstract description 8
230000003993 interaction Effects 0.000 abstract description 7
238000009472 formulation Methods 0.000 abstract description 5
DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical class C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 89
229960005132 cisapride Drugs 0.000 description 81
DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 80
230000000694 effects Effects 0.000 description 56
OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 description 40
238000012360 testing method Methods 0.000 description 27
229940079593 drug Drugs 0.000 description 23
230000002411 adverse Effects 0.000 description 17
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
210000004027 cell Anatomy 0.000 description 15
239000003446 ligand Substances 0.000 description 13
230000009471 action Effects 0.000 description 11
239000004480 active ingredient Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
239000008280 blood Substances 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000007788 liquid Substances 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
150000003936 benzamides Chemical class 0.000 description 9
230000027455 binding Effects 0.000 description 9
208000015114 central nervous system disease Diseases 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
239000000243 solution Substances 0.000 description 9
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 7
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 7
230000004060 metabolic process Effects 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
208000004998 Abdominal Pain Diseases 0.000 description 6
208000002881 Colic Diseases 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000001270 agonistic effect Effects 0.000 description 6
230000003042 antagnostic effect Effects 0.000 description 6
230000036772 blood pressure Effects 0.000 description 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
229960004316 cisplatin Drugs 0.000 description 6
230000002526 effect on cardiovascular system Effects 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000000843 powder Substances 0.000 description 6
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
230000007958 sleep Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
108091005482 5-HT4 receptors Proteins 0.000 description 5
206010012735 Diarrhoea Diseases 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
230000002503 metabolic effect Effects 0.000 description 5
239000011148 porous material Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
241000906446 Theraps Species 0.000 description 4
108010005774 beta-Galactosidase Proteins 0.000 description 4
102000005936 beta-Galactosidase Human genes 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000012549 training Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282339 Mustela Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
229940125683 antiemetic agent Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000003684 cardiac depression Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
230000009931 harmful effect Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229960003712 propranolol Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
230000035488 systolic blood pressure Effects 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
108091005477 5-HT3 receptors Proteins 0.000 description 2
102000035037 5-HT3 receptors Human genes 0.000 description 2
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
206010003011 Appendicitis Diseases 0.000 description 2
229930003347 Atropine Natural products 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
206010048610 Cardiotoxicity Diseases 0.000 description 2
201000003066 Diffuse Scleroderma Diseases 0.000 description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
102000002464 Galactosidases Human genes 0.000 description 2
108010093031 Galactosidases Proteins 0.000 description 2
208000018522 Gastrointestinal disease Diseases 0.000 description 2
206010017999 Gastrointestinal pain Diseases 0.000 description 2
101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
206010068871 Myotonic dystrophy Diseases 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
240000006394 Sorghum bicolor Species 0.000 description 2
235000011684 Sorghum saccharatum Nutrition 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
235000009430 Thespesia populnea Nutrition 0.000 description 2
VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
229960002054 acenocoumarol Drugs 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
229960004373 acetylcholine Drugs 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
229960000396 atropine Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
-1 but not limited to: depression Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
231100000259 cardiotoxicity Toxicity 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
208000010643 digestive system disease Diseases 0.000 description 2
229960005156 digoxin Drugs 0.000 description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
238000009509 drug development Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000002322 enterochromaffin cell Anatomy 0.000 description 2
229960004756 ethanol Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
239000003365 glass fiber Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229960004715 morphine sulfate Drugs 0.000 description 2
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
230000008855 peristalsis Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000002325 prokinetic agent Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
229960000620 ranitidine Drugs 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
229960000351 terfenadine Drugs 0.000 description 2
QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
VTXYPPVXMJMLCY-UHFFFAOYSA-N 2-piperidin-1-ylbenzamide Chemical compound NC(=O)C1=CC=CC=C1N1CCCCC1 VTXYPPVXMJMLCY-UHFFFAOYSA-N 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
208000027534 Emotional disease Diseases 0.000 description 1
208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
241000581650 Ivesia Species 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000282341 Mustela putorius furo Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010040925 Skin striae Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000003994 anesthetic gas Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
229960004754 astemizole Drugs 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
229960004841 cefadroxil Drugs 0.000 description 1
NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229940105442 cisplatin injection Drugs 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002895 emetic Substances 0.000 description 1
230000000095 emetic effect Effects 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
230000007160 gastrointestinal dysfunction Effects 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
208000008384 ileus Diseases 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940090044 injection Drugs 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
210000001853 liver microsome Anatomy 0.000 description 1
210000000111 lower esophageal sphincter Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229940068938 morphine injection Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
210000003249 myenteric plexus Anatomy 0.000 description 1
OQYITJFGEOOJPO-UHFFFAOYSA-N n-(3-hydroxypiperidin-4-yl)benzamide Chemical class OC1CNCCC1NC(=O)C1=CC=CC=C1 OQYITJFGEOOJPO-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
OMLDMGPCWMBPAN-UHFFFAOYSA-N norcisapride Chemical compound COC1CNCCC1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-UHFFFAOYSA-N 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000019525 primary metabolic process Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000344 soap Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG102757A 1996-07-19 1998-09-09 Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система BG63190B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/684,753 US5739151A (en)	1996-07-19	1996-07-19	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en)	1996-07-19	1997-07-02	Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (2)

Publication Number	Publication Date
BG102757A BG102757A (en)	1999-08-31
BG63190B1 true BG63190B1 (bg)	2001-06-29

Family

ID=24749413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102757A BG63190B1 (bg)	1996-07-19	1998-09-09	Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система

Country Status (25)

Country	Link
US (3)	US5739151A (de)
EP (1)	EP0896539B1 (de)
JP (1)	JP3097697B2 (de)
KR (4)	KR100533237B1 (de)
CN (1)	CN1215992A (de)
AT (1)	ATE197762T1 (de)
AU (1)	AU3592097A (de)
BG (1)	BG63190B1 (de)
BR (1)	BR9708287A (de)
CA (1)	CA2245768C (de)
CZ (1)	CZ293478B6 (de)
DE (1)	DE69703617T2 (de)
DK (1)	DK0896539T3 (de)
ES (1)	ES2152687T3 (de)
GR (1)	GR3035460T3 (de)
HU (1)	HUP9904360A3 (de)
IL (1)	IL125703A0 (de)
IS (1)	IS4820A (de)
NO (2)	NO317178B1 (de)
NZ (1)	NZ331291A (de)
PL (1)	PL189610B1 (de)
PT (1)	PT896539E (de)
SK (1)	SK282673B6 (de)
TR (1)	TR199801816T2 (de)
WO (1)	WO1998003173A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en)	1996-07-19	2000-11-14	Sepracor Inc.	Methods for treating gastroesophageal reflux disease
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
KR100469030B1 (ko) *	1996-10-15	2005-01-31	얀센 파마슈티카 엔.브이.	시사프라이드의 합성방법
HUP0003078A3 (en) *	1997-07-11	2002-02-28	Janssen Pharmaceutica Nv	(+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
EP1468685A3 (de) *	1998-06-15	2004-12-15	Sepracor Inc.	Verwendung von optisch reines (+)-Norcisapride für die Behandlung von Apnea, Bulimia und andere Krankheiten
EP1464333A3 (de) *	1998-06-15	2004-12-15	Sepracor Inc.	Verwendung von optisch reines (-) Norcisapride in der Behandlung von Apnea, Bulimia und andere Krankheiten
TR200003707T2 (tr) *	1998-06-15	2001-06-21	Sepracor Inc.	Apne , bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
KR20060067986A (ko) *	1998-06-15	2006-06-20	세프라코 아이엔시.	무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도
ID28510A (id) *	1998-08-21	2001-05-31	Novartis Ag	Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
US6353005B1 (en)	1999-03-02	2002-03-05	Sepracor, Inc.	Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en)	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en)	1999-03-19	2004-10-12	Abbott Gmbh & Co. Kg	Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
EP1321142A1 (de) *	2001-12-21	2003-06-25	Novartis AG	Feste orale Zubereitung mit Tegaserod
FR2854072B1 (fr) *	2003-04-23	2006-08-04	Centre Nat Rech Scient	Vecteur pour administration par voie orale
US8138204B2 (en) *	2004-01-07	2012-03-20	Aryx Therapeutics, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en)	2004-01-07	2013-09-03	Armetheon, Inc.	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
CA2551686C (en)	2004-01-07	2014-09-23	Ian Irwin	Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) *	2004-09-14	2009-07-02	Guy Debonnel	Stimulators of 5-HT4 receptors and uses thereof
EP1919909B1 (de) *	2005-08-31	2013-08-21	Armetheon, Inc.	Synthetische verfahren und zwischenprodukte für stereoisomere verbindungen, die sich für die behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems eignen
WO2007149929A1 (en) *	2006-06-23	2007-12-27	Aryx Therapeutics, Inc.	Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US20120208892A1 (en)	2009-10-16	2012-08-16	Epiomed Therapeutics, Inc.	Emesis treatment
ES2587304T3 (es) *	2011-02-25	2016-10-21	Yuhan Corporation	Derivados de diaminopirimidina y procedimientos para la preparación de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5057525A (en) *	1981-10-01	1991-10-15	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) *	1981-10-01	1992-08-11	Janssen Pharmaceutica N.V.	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) *	1981-10-01	1990-10-09	Janssen Pharmaceutica N.V.	Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) *	1981-10-01	1985-03-12	Georges Van Daele	N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114714A (en) *	1990-11-29	1992-05-19	Sepracor, Inc.	Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) *	1990-11-29	1992-05-19	Sepracor Inc.	Methods of use and compositions of (s)-isoflurane and (s)-desflurane
EP1145715A3 (de) *	1992-07-07	2004-05-19	Sepracor Inc.	Verfahren zur Verwendung von (-) Cisapride zur Behandlung von Magenspeiseroehrenruechstornung und anderen Erkrankungen
EP0651639A4 (de) *	1992-07-07	1996-06-26	Sepracor Inc	Verfahren zur verwendung von (+)-cisaprid zur behandlung der reflux-ösophagitis und anderer erkrankungen.
AU7397194A (en) *	1993-07-06	1995-02-06	Mcneil-Ppc, Inc.	H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) *	1995-06-07	1998-01-27	Sepracor, Inc.	Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) *	1996-07-19	1998-04-14	Sepracor Inc.	Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

1996
- 1996-07-19 US US08/684,753 patent/US5739151A/en not_active Expired - Fee Related
1997
- 1997-07-02 WO PCT/US1997/011629 patent/WO1998003173A1/en not_active Ceased
- 1997-07-02 JP JP10506954A patent/JP3097697B2/ja not_active Expired - Fee Related
- 1997-07-02 CN CN97192157A patent/CN1215992A/zh active Pending
- 1997-07-02 IL IL12570397A patent/IL125703A0/xx unknown
- 1997-07-02 CA CA002245768A patent/CA2245768C/en not_active Expired - Fee Related
- 1997-07-02 DK DK97932467T patent/DK0896539T3/da active
- 1997-07-02 AU AU35920/97A patent/AU3592097A/en not_active Abandoned
- 1997-07-02 ES ES97932467T patent/ES2152687T3/es not_active Expired - Lifetime
- 1997-07-02 DE DE69703617T patent/DE69703617T2/de not_active Expired - Fee Related
- 1997-07-02 KR KR10-2003-7013889A patent/KR100533237B1/ko not_active Expired - Fee Related
- 1997-07-02 KR KR10-2001-7011625A patent/KR100422492B1/ko not_active Expired - Fee Related
- 1997-07-02 PT PT97932467T patent/PT896539E/pt unknown
- 1997-07-02 TR TR1998/01816T patent/TR199801816T2/xx unknown
- 1997-07-02 EP EP97932467A patent/EP0896539B1/de not_active Expired - Lifetime
- 1997-07-02 PL PL97335254A patent/PL189610B1/pl not_active IP Right Cessation
- 1997-07-02 AT AT97932467T patent/ATE197762T1/de not_active IP Right Cessation
- 1997-07-02 SK SK1239-98A patent/SK282673B6/sk unknown
- 1997-07-02 KR KR10-2001-7011626A patent/KR100399808B1/ko not_active Expired - Fee Related
- 1997-07-02 HU HU9904360A patent/HUP9904360A3/hu unknown
- 1997-07-02 BR BR9708287-2A patent/BR9708287A/pt not_active Application Discontinuation
- 1997-07-02 NZ NZ331291A patent/NZ331291A/en unknown
- 1997-07-02 KR KR1019980706152A patent/KR100328731B1/ko not_active Expired - Fee Related
- 1997-07-02 CZ CZ19982508A patent/CZ293478B6/cs not_active IP Right Cessation
- 1997-08-05 US US08/905,941 patent/US5877188A/en not_active Expired - Fee Related
1998
- 1998-07-13 US US09/114,319 patent/US6114356A/en not_active Expired - Fee Related
- 1998-08-07 NO NO19983636A patent/NO317178B1/no unknown
- 1998-08-10 IS IS4820A patent/IS4820A/is unknown
- 1998-09-09 BG BG102757A patent/BG63190B1/bg unknown
2001
- 2001-02-22 GR GR20010400294T patent/GR3035460T3/el not_active IP Right Cessation
2004
- 2004-03-19 NO NO20041166A patent/NO20041166L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ250898A3 (cs)	1999-04-14
IS4820A (is)	1998-08-10
NO983636D0 (no)	1998-08-07
US5739151A (en)	1998-04-14
PT896539E (pt)	2001-05-31
ATE197762T1 (de)	2000-12-15
CZ293478B6 (cs)	2004-05-12
KR100533237B1 (ko)	2005-12-05
PL335254A1 (en)	2000-04-10
NZ331291A (en)	2000-06-23
BG102757A (en)	1999-08-31
BR9708287A (pt)	2000-01-18
KR100328731B1 (ko)	2002-10-19
GR3035460T3 (en)	2001-05-31
CA2245768C (en)	2003-09-30
DK0896539T3 (da)	2001-02-19
JPH11510828A (ja)	1999-09-21
NO317178B1 (no)	2004-09-06
US6114356A (en)	2000-09-05
TR199801816T2 (xx)	2000-10-23
KR100422492B1 (ko)	2004-03-11
IL125703A0 (en)	1999-04-11
HUP9904360A2 (hu)	2000-05-28
KR20040007505A (ko)	2004-01-24
HUP9904360A3 (en)	2001-07-30
NO983636L (no)	1998-10-19
AU3592097A (en)	1998-02-10
JP3097697B2 (ja)	2000-10-10
SK123998A3 (en)	1999-03-12
ES2152687T3 (es)	2001-02-01
PL189610B1 (pl)	2005-08-31
KR20000064524A (ko)	2000-11-06
DE69703617T2 (de)	2001-04-12
CA2245768A1 (en)	1998-01-29
KR100399808B1 (ko)	2003-09-29
SK282673B6 (sk)	2002-11-06
US5877188A (en)	1999-03-02
NO20041166L (no)	2004-03-19
EP0896539A1 (de)	1999-02-17
WO1998003173A1 (en)	1998-01-29
EP0896539B1 (de)	2000-11-29
DE69703617D1 (de)	2001-01-04
CN1215992A (zh)	1999-05-05

Publication	Publication Date	Title
EP0896539B1 (de)	2000-11-29	Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
EP0831821B1 (de)	2004-07-28	Optisch reines (-) norcisaprid zur behandlung von krankheiten des verdauungstrakt
US6632827B2 (en)	2003-10-14	Compositions of optically pure (+) norcisapride
AU780107B2 (en)	2005-03-03	Methods for treating emesis and central nervous system disorders using optically pure () norcisapride
MXPA01000919A (en)	2002-03-26	Methods and compositions for treating gastro-esophageal reflux disease